BIOCEO Investor Conference (Oncothyreon) - Feb 15, 2011 - PX-866 / Oncothyreon; Initiation of single agent P2 trials expected in Q2 '11 & P2 data expected in H2 '11 & H1 '12; Anticipated trials for chemotherapy naive prostrate & glioblastoma in Q2 '11; Anticipated Health Canada approval in 2011
Anticipated P2 data • Anticipated P2 trial initiation • Oncology
|